Washington University School of Medicine in St. Louis is radically advancing immunotherapy treatments and personalized cancer therapies. PICI researcher Robert D. Schreiber, PhD, has championed the power of immunotherapy for more than 25 years. He translates basic research principles into clinical trials and drives new therapeutic approaches. Matthew Gubin, PhD, Parker Bridge Scholar, works in Schreiber’s lab researching tumor growth and rejection to improve responses to checkpoint blockade therapies. Together with PICI, they focus on T-cells and activating responses for more patients and more cancer types. Robert D. Schreiber, PhD | Investigator Matthew Gubin, PhD | Bridge Scholar Related Research Project Tumor Neoantigen Selection Alliance (TESLA) Research Focus Tumor Antigen Discovery: Targeting Cancer Research Project Brain Tumor Program Point of View How to Engage Your Employees During a Pandemic Our Impact, Patient Story A Legacy of Service and a New Day for Pancreatic Cancer Cancer Research Heroes, Our Impact The Power and Promise of High-Risk Science Announcement, Our Impact, Press Release, Research Update Neoantigen Alliance IDs Parameters for Cancer Vaccines Announcement, Press Release PICI Appoints John Connolly as Chief Scientific Officer Research Project CANDEL: A first-of-its-kind data analysis engine for scientific discovery
Announcement, Our Impact, Press Release, Research Update Neoantigen Alliance IDs Parameters for Cancer Vaccines